Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Clin Imaging. 2016 Jun 13;40(5):1047–1054. doi: 10.1016/j.clinimag.2016.06.002

Fig. 5.

Fig. 5

35-year-old woman with personal history of right breast inflammatory ductal carcinoma on neoadjuvant chemotherapy. The patient underwent breast MR imaging for high-risk screening. A, Axial dynamic contrast-enhanced initial post-contrast subtraction MR image with magnified inset shows a new 7-mm homogeneously enhancing mass (arrow) at 8 o’clock of the left breast, 56-mm from the nipple. The lesion has smooth margin and is at middle depth. This lesion was classified as BI-RADS category 4. B, Axial dynamic contrast-enhanced MR image shows the lesion (arrow) has mixed kinetics overall: medium initial uptake with predominantly delayed persistent enhancement (blue). C, ADC map shows the lesion exhibits high ADC (mean, = 2.36 ×10−3 mm2/s), measured within the corresponding region-of-interest (yellow contour). The lesion was classified as fibroadenoma on the basis of ultrasound-guided core biopsy. D, Hematoxylin-eosin stain with original magnification, ×100 demonstrates epithelial hyperplasia, low stromal cellularity, no immune cell infiltration and loose stroma.